Barely Significant
← all excerpts

Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).

Oncologist · 2026 · PMC13033234 · PMID 41832993

Europe PMCDOI
1
hedged sentence
0.0440
closest p · 0.9× alpha
0.0440
boldest claim

The sentences

nominally significantP = .044actually significant
Only the NTB for thrombocytopenia was nominally significant in favor of UFT, though the effect size was quite small (NTB = −0.8%; 95% CI, −1.6 to −0.0%; P = .044).

also in 4,767 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.